Quality System Requirements May Boost Clinical Trial Compliance
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers should incorporate a corrective and preventive action program and management controls into their oversight of clinical trials, according to CDRH Bioresearch Monitoring Director Michael Marcarelli